About

Chugais strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai originated innovative new drug candidates. Chugai is one of Japans leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugais strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. Chugai has recently established Translational Clinical Research Division (TCRD) as its first global organization, composed of TCR functions in Japan, Europe, and U.S. (CPUSA). The division specializes in early clinical development of Chugai origin pipeline products, and aims to accelerate PoC for rapid shift to global development. Some of Chugais global development achievements that exemplify first-in-class/best-in-class include: Actemra (tocilizumab)                 first-in-class IL-6 signal blockade agent for rheumatoid arthritis and other autoimmune diseases Alecensa (alectinib)                      new generation ALK inhibitor for non-small cell lung cancer launched in Japan and under clinical development in US (by Roche) with Breakthrough Therapy designation by the FDA GC33                     anti-glypican 3 monoclonal antibody for hepatocellular carcinoma under co-development with Roche ACE910                 anti-factor IXa/X bispecific antibody, novel concept treatment for hemophilia A under co-development with Roche